참고문헌
- Au NH, Cheang M, Huntsman DG, et al (2004). Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol, 204, 101-9. https://doi.org/10.1002/path.1612
- Bendell JC, Rodon J, Burris HA, et al (2012). Phase I, doseescalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol, 30, 282-90. https://doi.org/10.1200/JCO.2011.36.1360
- Bepler G, Sharma S, Cantor A, et al (2004). RRM and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol, 22, 1878-85. https://doi.org/10.1200/JCO.2004.12.002
- Cagle PT, Chirieac LR (2012). Advances in treatment of lung cancer targeted therapy. Arch Pathol Lab Med, 136, 504-9. https://doi.org/10.5858/arpa.2011-0618-RA
- Chu EC, Tarnawski AS (2004). PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit, 10, 235-41.
- Citri A, Yarden Y (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 7, 505-16. https://doi.org/10.1038/nrm1962
- Gatzemeier U, Groth G, Butts C, et al (2004). Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol, 15, 19-27. https://doi.org/10.1093/annonc/mdh031
- Hirsch FR, Varella-Garcia M, Franklin WA, et al (2002). Evaluation of HER-2/neu gene amplification and protein expression in nonsmall cell lung carcinomas. Br J Cancer, 86, 1449-56. https://doi.org/10.1038/sj.bjc.6600286
- Jemal A, Bray F, Center M, et al (2011). Global Cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jin G, Kim MJ, Jeon HS, et al (2010). PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer, 69, 279-83. https://doi.org/10.1016/j.lungcan.2009.11.012
- Kang YH, Lee HS, Kim WH (2002). Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest, 82, 285-91. https://doi.org/10.1038/labinvest.3780422
- Lee SY, Kim MJ, Jin G, et al (2010). Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol, 5, 1734-40. https://doi.org/10.1097/JTO.0b013e3181f0beca
- Lim WT, Zhang WH, Miller CR, et al (2007). PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep, 17, 853-7.
- Liu L, Shao X, Gao W, et al (2010). The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol, 5, 1922-32. https://doi.org/10.1097/JTO.0b013e3181f26266
- Maira SM, Stauffer F, Schnell C, Garcia-Echeverrıa C (2009). PI3K inhibitors for cancer treatment: where do we stand. Biochem Soc Trans, 37, 265-72. https://doi.org/10.1042/BST0370265
- Marsit CJ, Zheng S, Aldape K, et al (2005). PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol, 36, 768-76. https://doi.org/10.1016/j.humpath.2005.05.006
- Meert AP, Martin B, Paesmans M, et al (2003). The role of HER- 2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer, 89, 959-65. https://doi.org/10.1038/sj.bjc.6601252
- Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008). Non-Small Cell Lung Cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94. https://doi.org/10.1016/S0025-6196(11)60735-0
- Nagata Y, Lan KH, Zhou X, et al (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6, 117-27. https://doi.org/10.1016/j.ccr.2004.06.022
- Nakamura H, Saji H, Ogata A, et al (2003). Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int J Cancer, 103, 61-6. https://doi.org/10.1002/ijc.10795
- O'Byrne KJ, Gatzemeier U, Bondarenko I, et al (2011). Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol, 12, 795-805. https://doi.org/10.1016/S1470-2045(11)70189-9
- Olaussen KA, Soria JC, Mοrat L, et al (2003). Loss of PTEN expression is not uncommon but lacks prognostic value in stage I NSCLC. Anticancer Res, 23, 4885-90.
- Pelosi G, Del CB, Dell'Orto P, et al (2005). Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer, 113, 101-8. https://doi.org/10.1002/ijc.20542
- Perez EA, Reinholz MM, Hillman DW, et al (2010). HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol, 28, 4307-15. https://doi.org/10.1200/JCO.2009.26.2154
- Sher T, Dy GK, Adjei AA (2008). Small cell lung cancer. Mayo Clin Proc, 83, 355-67. https://doi.org/10.4065/83.3.355
- Shoman N, Klassen S, McFadden A, et al (2005). Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol, 18, 250-9. https://doi.org/10.1038/modpathol.3800296
- Song MS, Salmena L, Pandolfi PP (2012). The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol, 13, 283-96. https://doi.org/10.1038/nrg3199
- Swanton C, Futreal A, Eisen T (2006). Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res, 12, 4377-83. https://doi.org/10.1158/1078-0432.CCR-06-0115
- Takenaka M, Hanagiri T, Shinohara S, et al (2011). The prognostic significance of HER2 overexpression in nonsmall cell lung cancer. Anticancer Res, 31, 4631-6.
- Tan D, Deeb G, Wang J, et al (2003). HER2 protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol, 12, 201-11. https://doi.org/10.1097/00019606-200312000-00004
- Tang JM, He QY, Guo RX, et al (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer, 51, 181-91. https://doi.org/10.1016/j.lungcan.2005.10.003
- Timotheadou E, Skarlos DV, Samantas E, et al (2007). Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Res, 27, 4481-9.
- Valabrega G, Montemurro F, Aglietta M (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol, 18, 977-84. https://doi.org/10.1093/annonc/mdl475
- Vogel CL, Cobleigh MA, Tripathy D, et al (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20, 719-26. https://doi.org/10.1200/JCO.20.3.719
- Wang L, Zhang Q, Zhang J, et al (2011). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 11, 248. https://doi.org/10.1186/1471-2407-11-248
- Wang L, Yue W, Zhang L, et al (2012). mTOR and PTEN expression in non-small cell lung cancer: analysis by realtime fluorescence quantitative polymerase chain reaction and immunohistochemistry. Surg Today, 42, 419-25. https://doi.org/10.1007/s00595-011-0028-1
- Yoo SB, Xu X, Lee HJ, et al (2011). Loss of PTEN expression is an independent poor prognostic factor in non-small cell lung cancer. Korean J Pathol, 45, 329-35. https://doi.org/10.4132/KoreanJPathol.2011.45.4.329
피인용 문헌
- Association of High LDH and Low Glucose Levels in Pleural Space with HER2 Expression in Non-Small Cell Lung Cancer vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1617
- Correlation of HER-2/Neu Protein Expression and HER2 Gene Amplification with Clinical Morphological Parameters of Nonsmall Cell Lung Cancer vol.157, pp.6, 2014, https://doi.org/10.1007/s10517-014-2668-9
- Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms in Gall Bladder Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5647